Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Last Close
1.62
Sep 04 • 3:59 PM ET Dollar change-0.14 Percentage change(-7.95%)
Aftermarket Close
1.68
Aftermarket • 7:58 PM ET Dollar change+0.06 Percentage change(3.46%)
Index
-
Market Cap
164.98M
Enterprise Value
121.76M
Income
-111.90M
Sales
25.25M
Book/sh
0.95
Cash/sh
1.10
Employees
-
IPO
Apr 28, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
6.53
P/B
1.71
P/C
1.48
P/FCF
-
EV/EBITDA
-
EV/Sales
4.82
Quick Ratio
2.29
Current Ratio
2.37
Debt/Eq
0.72
LT Debt/Eq
0.44
Option/Short
No / Yes
EPS (ttm)
-2.52
EPS next Y
-0.79
EPS next Q
-0.35
EPS this Y
52.59%
EPS next Y
38.81%
EPS next 5Y
43.71%
EPS past 3/5Y
-28.04% -28.17%
Sales past 3/5Y
51.67% 170.10%
EPS Y/Y TTM
-9.99%
Sales Y/Y TTM
369.67%
EPS Q/Q
-7.74%
Sales Q/Q
487.55%
Insider Own
20.18%
Insider Trans
0.00%
Inst Own
22.83%
Inst Trans
12.17%
ROA
-67.96%
ROE
-123.53%
ROIC
-81.97%
Gross Margin
30.34%
Oper. Margin
-393.88%
Profit Margin
-443.15%
SMA20
1.16%
SMA50
2.94%
SMA200
-49.09%
Trades
Shs Outstand
100.07M
Shs Float
81.29M
52W High
6.87 -76.43%
52W Low
1.26 28.57%
Volatility
7.08% 5.01%
ATR (14)
0.10
RSI (14)
51.97
Beta
1.64
Rel Volume
2.25
Avg Volume
448.91K
Volume
1,007,997
Perf Week
1.25%
Perf Month
23.66%
Perf Quarter
11.72%
Perf Half Y
-56.68%
Perf YTD
-64.78%
Perf Year
-71.58%
Perf 3Y
-78.41%
Perf 5Y
-94.76%
Perf 10Y
-
Prev Close
1.76
Price
1.62
Change %
-7.95%
Date Action Analyst Rating Change Price Target Change
May-12-26Downgrade Stifel Buy → Hold $5
Jul-31-23Initiated H.C. Wainwright Buy
Jul-19-23Initiated Robert W. Baird Neutral
Apr-21-22Initiated Oppenheimer Outperform $30
Apr-06-22Initiated Wolfe Research Peer Perform $21
Dec-21-21Resumed Cantor Fitzgerald Overweight $47
Jul-28-21Initiated Cantor Fitzgerald Overweight $43
Sep-02-26 04:05PM
Aug-25-26 04:30PM
Aug-06-26 01:07AM
Aug-05-26 04:05PM
Aug-04-26 09:50AM
04:05PM Loading…
Jul-27-26 04:05PM
Jul-07-26 04:05PM
Jun-30-26 04:30PM
Jun-29-26 04:30PM
Jun-23-26 04:05PM
Jun-19-26 04:30PM
Jun-17-26 04:30PM
04:05PM
Jun-15-26 04:05PM
Jun-10-26 05:00PM
04:30PM Loading…
04:30PM
04:05PM
Jun-05-26 12:58PM
11:25AM
Jun-04-26 04:02PM
04:01PM
May-20-26 04:30PM
04:05PM
May-13-26 01:01AM
May-12-26 04:05PM
May-11-26 09:22AM
May-08-26 04:05PM
Apr-30-26 04:05PM
Apr-28-26 04:05PM
Mar-20-26 05:30PM
01:00AM Loading…
01:00AM
Mar-19-26 04:10PM
Mar-18-26 09:22AM
Mar-13-26 05:30PM
Mar-11-26 05:05PM
Mar-05-26 04:05PM
Mar-04-26 05:55PM
Feb-27-26 04:30PM
Feb-25-26 04:30PM
Feb-18-26 04:05PM
Jan-21-26 04:05PM
Jan-12-26 04:05PM
01:00AM
Dec-29-25 04:05PM
Dec-19-25 04:05PM
Dec-17-25 01:05AM
Dec-02-25 04:30PM
Dec-01-25 09:14AM
Nov-27-25 04:05PM
Nov-26-25 01:45AM
Nov-23-25 08:00PM
Nov-20-25 04:30PM
Nov-13-25 07:30PM
05:55PM
04:12PM
Nov-12-25 07:30AM
Nov-06-25 07:15AM
Nov-03-25 04:05PM
Oct-30-25 05:10PM
10:00AM
Oct-29-25 10:00AM
Oct-07-25 12:30PM
Oct-06-25 01:00AM
Oct-03-25 04:30PM
Oct-02-25 09:10AM
Sep-23-25 04:10PM
Sep-15-25 04:10PM
Sep-05-25 04:30PM
Sep-02-25 04:30PM
Aug-29-25 04:30PM
Aug-18-25 04:10PM
Aug-15-25 10:10AM
09:18AM
Aug-11-25 07:00PM
01:00AM
Aug-08-25 04:10PM
Aug-07-25 07:10AM
Aug-06-25 05:55PM
Jul-29-25 04:45PM
04:30PM
Jul-28-25 04:05PM
Jun-27-25 04:30PM
Jun-13-25 01:00AM
May-30-25 04:30PM
May-28-25 04:30PM
May-23-25 04:30PM
May-14-25 07:35AM
01:00AM
May-09-25 04:30PM
01:00AM
May-08-25 07:15AM
May-07-25 05:15PM
04:30PM
May-06-25 05:55PM
Apr-16-25 02:00AM
Apr-08-25 01:00AM
Mar-26-25 03:00AM
Mar-13-25 02:00AM
Mar-10-25 05:05PM
Mar-03-25 04:30PM
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
Co-Founder & ChairmanMr. Robert Taub MBA
CEO & Executive DirectorMr. Olivier Taelman
Chief Technical OfficerMr. Bruno Onkelinx
Chief Financial OfficerMr. John Landry
Chief Science OfficerMr. Jeyakumar Subbaroyan